BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gutierrez-Reyes G, Lopez-Ortal P, Sixtos S, Cruz S, Ramirez-Iglesias MT, Gutierrez-Ruiz MC, Sanchez-Avila F, Roldan E, Vargas-Vorackova F, Kershenobich D. Effect of pentoxifylline on levels of pro-inflammatory cytokines during chronic hepatitis C. Scand J Immunol. 2006;63:461-467. [PMID: 16764700 DOI: 10.1111/j.1365-3083.2006.001761.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Gonzalez-Fajardo L, Fernández OL, McMahon-Pratt D, Saravia NG. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators. PLoS Negl Trop Dis 2015;9:e0003820. [PMID: 26024228 DOI: 10.1371/journal.pntd.0003820] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
2 Eşrefoğlu M, Gül M, Turan F. Comparative effects of several therapatic agents on hepatic damage induced by acute experimental pancreatitis. Dig Dis Sci 2008;53:1303-10. [PMID: 17934852 DOI: 10.1007/s10620-007-0007-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
3 Metwally AH. Pentoxifylline in the management of metabolic syndrome and chronic hepatitis C. Med Hypotheses 2014;83:832-4. [PMID: 25468788 DOI: 10.1016/j.mehy.2014.10.020] [Reference Citation Analysis]
4 Vircheva S, Alexandrova A, Georgieva A, Mateeva P, Zamfirova R, Kubera M, Kirkova M. In vivo effects of pentoxifylline on enzyme and non-enzyme antioxidant levels in rat liver after carrageenan-induced paw inflammation. Cell Biochem Funct 2010;28:668-72. [PMID: 21104934 DOI: 10.1002/cbf.1705] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
5 Chen YH, de Carvalho HM, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS. Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice. Biologics 2018;12:1-9. [PMID: 29391775 DOI: 10.2147/BTT.S148606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Melo ML, Brito GA, Soares RC, Carvalho SB, Silva JV, Soares PM, Vale ML, Souza MH, Cunha FQ, Ribeiro RA. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol. 2008;61:775-784. [PMID: 17624531 DOI: 10.1007/s00280-007-0534-4] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 4.7] [Reference Citation Analysis]
7 Albayrak A, Uyanik MH, Cerrah S, Altas S, Dursun H, Demir M, Uslu H. Is HMGB1 a New Indirect Marker for Revealing Fibrosis in Chronic Hepatitis and a New Therapeutic Target in Treatment? Viral Immunology 2010;23:633-8. [DOI: 10.1089/vim.2010.0080] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
8 Assem M, Yousri M. Impact of pentoxifylline and vitamin e on ribavirin-induced haemolytic anaemia in chronic hepatitis C patients: an egyptian survey. Int J Hepatol 2011;2011:530949. [PMID: 21994862 DOI: 10.4061/2011/530949] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Gruber S, Schmidt M, Bozsaky E, Wolfram K, Haagen J, Habelt B, Puttrich M, Dörr W. Modulation of radiation-induced oral mucositis by pentoxifylline: Preclinical studies. Strahlenther Onkol 2015;191:242-7. [DOI: 10.1007/s00066-014-0775-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
10 Assem M, Yousri M. Impact of Pentoxifylline and Vitamin E on Ribavirin-induced Hemolytic Anemia in Chronic Hepatitis C Patients: An Egyptian Survey. Euroasian Journal of Hepato-Gastroenterology 2012;2:35-40. [DOI: 10.5005/jp-journals-10018-1029] [Reference Citation Analysis]
11 Brito G, Dourado M, Polari L, Celestino D, Carvalho LP, Queiroz A, Carvalho EM, Machado PR, Passos S. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. Am J Trop Med Hyg 2014;90:617-20. [PMID: 24567316 DOI: 10.4269/ajtmh.12-0729] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
12 Hendawy N. Pentoxifylline attenuates cytokine stress and Fas system in syngeneic liver proteins induced experimental autoimmune hepatitis. Biomedicine & Pharmacotherapy 2017;92:316-23. [DOI: 10.1016/j.biopha.2017.05.084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Wen WX, Lee SY, Siang R, Koh RY. Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. Adv Ther 2017;34:1245-69. [PMID: 28484954 DOI: 10.1007/s12325-017-0547-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
14 McCarty MF, O'Keefe JH, DiNicolantonio JJ. Pentoxifylline for vascular health: a brief review of the literature. Open Heart 2016;3:e000365. [PMID: 26870389 DOI: 10.1136/openhrt-2015-000365] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
15 Gutierrez-Reyes G, Gutierrez-Ruiz MC, Kershenobich D. Liver fibrosis and chronic viral hepatitis. Arch Med Res 2007;38:644-51. [PMID: 17613356 DOI: 10.1016/j.arcmed.2006.10.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
16 Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, Adinolfi LE. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 5(10): 528-540 [PMID: 24179612 DOI: 10.4254/wjh.v5.i10.528] [Cited by in Crossref: 123] [Cited by in F6Publishing: 118] [Article Influence: 13.7] [Reference Citation Analysis]
17 Ventin F, Cincurá C, Machado PRL. Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis. Expert Rev Anti Infect Ther 2018;16:219-25. [PMID: 29411659 DOI: 10.1080/14787210.2018.1436967] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
18 McArthur MA, Holbrook MR. Japanese Encephalitis Vaccines. J Bioterror Biodef 2011;S1:2. [PMID: 23125946 DOI: 10.4172/2157-2526.S1-002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
19 Mohamed DI, Elmelegy AASM, A. El-aziz LF, Abdel kawy HS, Abdel-samad AA, El-kharashi OA. Hepatoprotective effects of early pentoxifylline administration on hepatic injury induced by concanavalin A in rat. Can J Physiol Pharmacol 2014;92:490-7. [DOI: 10.1139/cjpp-2014-0085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
20 Machado PRL, Lessa H, Lessa M, Guimaraes LH, Bang H, Ho JL, Carvalho EM. Oral Pentoxifylline Combined with Pentavalent Antimony: A Randomized Trial for Mucosal Leishmaniasis. Clinical Infectious Diseases 2007;44:788-93. [DOI: 10.1086/511643] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 6.5] [Reference Citation Analysis]
21 Castro MDM, Cossio A, Navas A, Fernandez O, Valderrama L, Cuervo-Pardo L, Marquez-Oñate R, Gómez MA, Saravia NG. Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia. Pathogens 2022;11:378. [PMID: 35335703 DOI: 10.3390/pathogens11030378] [Reference Citation Analysis]